Global Markets Direct’s, ‘Mantle Cell Lymphoma - Pipeline Review, H1 2016’, provides an overview of the Mantle Cell Lymphoma pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Mantle Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mantle Cell Lymphoma and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
- The report provides a snapshot of the global therapeutic landscape of Mantle Cell Lymphoma - The report reviews pipeline therapeutics for Mantle Cell Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Mantle Cell Lymphoma therapeutics and enlists all their major and minor projects - The report assesses Mantle Cell Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Mantle Cell Lymphoma
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Mantle Cell Lymphoma - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Mantle Cell Lymphoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Our reports have been used by over 10K customers, including:
The Global Oncology Partnering 2015-2021: Deal trends, players and financials report provides an understanding and access to the oncology partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in Oncology partnering deals Financial deal terms for headline, upfront and royalty...
Global Flow Cytometry in Oncology Market to Reach $5.25 Billion by 2031 Market Report Coverage - Flow Cytometry in Oncology Market Segmentation • Product Type – Assays and Kits, Instruments, Reagents and Consumables, and Software • Technology – Cell-Based and Bead-Based • Type of...
“Gastrointestinal Stromal Tumors - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Gastrointestinal Stromal Tumors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type,...
Refractory Multiple Myeloma (Oncology) - Drugs in Development, 2021 Summary Refractory Multiple Myeloma (Oncology) - Drugs in Development, 2021 provides an overview of the Refractory Multiple Myeloma pipeline landscape. The report provides comprehensive information on the therapeutics under...
Pituitary Tumor (Oncology) - Drugs in Development, 2021 Summary Pituitary Tumor (Oncology) - Drugs in Development, 2021 provides an overview of the Pituitary Tumor pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pituitary Tumor, complete...
Pleomorphic Liposarcoma (Oncology) - Drugs in Development, 2021 Summary Pleomorphic Liposarcoma (Oncology) - Drugs in Development, 2021 provides an overview of the Pleomorphic Liposarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development...
Angiosarcoma (Oncology) - Drugs in Development, 2021 Summary Angiosarcoma (Oncology) - Drugs in Development, 2021 provides an overview of the Angiosarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Angiosarcoma, complete with...
Ubiquitin Protein Ligase E3A (Renal Carcinoma Antigen NY REN 54 or Human Papillomavirus E6 Associated Protein or Oncogenic Protein Associated Protein E6 AP or E6AP Ubiquitin Protein Ligase or UBE3A or EC 188.8.131.52) - Drugs in Development, 2021 Summary Ubiquitin Protein Ligase E3A (Renal Carcinoma...
198 pages •
By Global Industry Analysts
• Apr 2021
- Global Doxorubicin Market to Reach $1.4 Billion by 2027
- Amid the COVID-19 crisis, the global market for Doxorubicin estimated at US$1 Billion in the year 2020, is projected to reach a revised size of US$1.4 Billion by 2027, growing at a CAGR of 5.2% over the analysis period 2020-2027. Breast Cancer,...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.